Agency for Healthcare Research and Quality

Advancing Excellence in Health Care • www.ahrq.gov

Panel 2: Providers and Payers

Implementation of Risk Minimization Action Plans to Support Quality Use of Pharmaceuticals; Opportunities and Challenges:

A Public Workshop

June 25 and 26, 2007

Advancing Excellence in Health Care

Perspectives

- Creators
- Marketers and distributors
- Prescribers
- Dispensers
- Payers
- Users

AHRQ
Advancing Excellence in Health Care

Perspectives

- Creators
- Marketers and distributors
- **Prescribers**
- Dispensers
- **Payers**
- Users

AHRQ
Advancing Excellence in Health Care

Agenda

- 1 pm Introductions
- 1:15 Payer perspective
- 1:30 CDS, CPOE, & large health systems
- 2:00 Clinician perspective
- 2:15 Audience discussion with panel
- 2:55 Wrap-up
- 3:00 End

Panelists

- Carole Redding Flamm, M.D., M.P.H.

  Blue Cross and Blue Shield Association
  - Currently, Executive Medical Director in BCBC's Office of Clinical Affairs
  - Previously Associate Director of the BCBC's Technology Evaluation Center
  - fellowship in clinical epidemiology and health services research at the Brigham and Women's Hospital in Boston
  - Medical Degree from the University of Pennsylvania
  - Master's Degree in Public Health from Harvard

Panelists

- Richard Wagner, Pharm.D.

  Kaiser Permanente

  - Kaiser Pharmacy leader in the areas of
    - formulary management,
    - drug information,
    - physician drug education,
    - outcomes research,
    - and pharmacy benefit management
  - Officer and member of California Society of Health Systems Pharmacists board of directors.

Panelists

- Peter Glassman, MBBS, M.Sc.
  Veteran's Administration
  - Staff Physician in the Department of Medicine at the VA Greater Los Angeles Healthcare System
  - Professor of Clinical Medicine in the Department of Medicine at UCLA
  - Affiliated Adjunct Staff at RAND Health, Santa Monica.
  - Co-Director of the VA Center for Medication Safety at Hines
  - Medical degree (MBBS) and Master of Sciences (M.Sc.) degree in Economics from the University of London
  - Residency in internal medicine at the University of Connecticut
  - Fellowship in amb. care and health services research at W. Los Angeles VA & UCLA

Panelists

- Wilson Pace, M.D.

  Practicing Family Physician
  - Professor of Family Medicine at the University of Colorado, School of Medicine,
  - Green Edelman Chair for Practice-based Research
  - Director of the American Academy of Family Physicians National Research Network.
  - Served on the Institute of Medicine's committee studying the recognition and prevention of medication errors which resulted in the report entitled "Preventing Medication Errors."
  - Principal Investigator on AHRQ, NIH, and foundation-funded research totaling over $5 million in past 6 years
  - MD degree from the University of California, Irvine

Advancing Excellence in Health Care

Ground Rules

- Each panelist will present for ~15 minutes

AHRQ
Advancing Excellence in Health Care

Task master

AHRQ
Advancing Excellence in Health Care

Ground Rules

- Each panelist will present for ~15 minutes
- After each panelists, one or two minutes for clarifying questions from audience
- If we stick to the ground rules, we will have >30 minutes for panel and audience discussion

AHRQ
Advancing Excellence in Health Care

Presentations

- Carole Redding Flamm, M.D., M.P.H.
  Blue Cross and Blue Shield Association
- Richard Wagner, Pharm.D.
  Kaiser Permanente
- Peter Glassman, MBBS, M.Sc.
  Veteran's Administration
- Wilson Pace, M.D.
  Practicing Family Physician

Questions

- Contrast between close systems and open systems in te[illegible] of dealing with [illegible]cal [illegible] and sharing data and how this affects the accessibility [illegible] data for [illegible]
- Co[illegible] lack of attention to the issues of care for children.
- What to do [illegible] of lack of direct head to head efficacy data
- [illegible] can consumers [illegible]vance eRx and PHR
- [illegible] process, a[illegible] effectiveness, multiple previous drugs, authori[illegible]
- [illegible]DA tries to ba[illegible]idance and a[illegible] how should FDA work with [illegible] effectively ([illegible]ment)
- Policies to p[illegible] care for chi[illegible]
- What is the algorithm for a pay[illegible] new dru[illegible] formularies
- Balancing efficacy vs safety in terms of new vs ol[illegible]
- FDA sees labeling as primary RiskMAP tool, but CPS uses more th[illegible] the label to develop protocols. Comment?
- How can companies who work with FDA, if multiple clicinal systems use it differently?

Final questions

- What type of information are payers and [illegible] looking for that are not included in [illegible]?
- How [illegible] the proprietary aspects of the [illegible] RiskMAP system?